PubRank

Ethan Dmitrovsky

Author PubWeight™ 75.84‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Expression profiling of mammalian microRNAs uncovers a subset of brain-expressed microRNAs with possible roles in murine and human neuronal differentiation. Genome Biol 2004 15.15
2 MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J Clin Invest 2010 2.87
3 Uncovering growth-suppressive MicroRNAs in lung cancer. Clin Cancer Res 2009 2.19
4 Retinoids in cancer therapy and chemoprevention: promise meets resistance. Oncogene 2003 2.02
5 The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice. Cancer Res 2007 1.81
6 Specific chemopreventive agents trigger proteasomal degradation of G1 cyclins: implications for combination therapy. Clin Cancer Res 2004 1.68
7 A novel retinoic acid receptor beta isoform and retinoid resistance in lung carcinogenesis. J Natl Cancer Inst 2005 1.67
8 Transgenic cyclin E triggers dysplasia and multiple pulmonary adenocarcinomas. Proc Natl Acad Sci U S A 2007 1.61
9 Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models. Cancer Prev Res (Phila) 2011 1.61
10 Evidence for the epidermal growth factor receptor as a target for lung cancer prevention. Clin Cancer Res 2002 1.61
11 A retinoic acid-dependent checkpoint in the development of CD4+ T cell-mediated immunity. J Exp Med 2011 1.41
12 Bexarotene and erlotinib for aerodigestive tract cancer. J Clin Oncol 2005 1.30
13 G0S2 is an all-trans-retinoic acid target gene. Int J Oncol 2008 1.23
14 Epidermal growth factor receptor tyrosine kinase inhibition represses cyclin D1 in aerodigestive tract cancers. Clin Cancer Res 2004 1.16
15 UBE1L is a retinoid target that triggers PML/RARalpha degradation and apoptosis in acute promyelocytic leukemia. Proc Natl Acad Sci U S A 2002 1.16
16 Involvement of UBE1L in ISG15 conjugation during retinoid-induced differentiation of acute promyelocytic leukemia. J Biol Chem 2004 1.14
17 Targeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastrophe. Clin Cancer Res 2009 1.10
18 A retinoic acid--rich tumor microenvironment provides clonal survival cues for tumor-specific CD8(+) T cells. Cancer Res 2012 1.09
19 UBE1L causes lung cancer growth suppression by targeting cyclin D1. Mol Cancer Ther 2008 1.09
20 Cyclin degradation for cancer therapy and chemoprevention. J Cell Biochem 2007 1.07
21 Hedgehog-producing cancer cells respond to and require autocrine Hedgehog activity. Cancer Res 2011 1.05
22 A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer. Clin Cancer Res 2007 1.04
23 Microarray analysis uncovers retinoid targets in human bronchial epithelial cells. Oncogene 2003 1.04
24 High DNA methyltransferase 3B expression mediates 5-aza-deoxycytidine hypersensitivity in testicular germ cell tumors. Cancer Res 2009 0.99
25 Cyclin E transgenic mice: discovery tools for lung cancer biology, therapy, and prevention. Cancer Prev Res (Phila) 2010 0.99
26 The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis. Mol Cancer Ther 2008 0.98
27 Anaphase catastrophe is a target for cancer therapy. Clin Cancer Res 2011 0.97
28 Involvement of microRNAs in lung cancer biology and therapy. Transl Res 2011 0.96
29 Blockade of the ubiquitin protease UBP43 destabilizes transcription factor PML/RARα and inhibits the growth of acute promyelocytic leukemia. Cancer Res 2010 0.96
30 Microarray analyses uncover UBE1L as a candidate target gene for lung cancer chemoprevention. Cancer Res 2004 0.95
31 Cyclin D1 as a target for chemoprevention. Lung Cancer 2003 0.95
32 UBE1L represses PML/RAR{alpha} by targeting the PML domain for ISG15ylation. Mol Cancer Ther 2008 0.94
33 Wnt pathway reprogramming during human embryonal carcinoma differentiation and potential for therapeutic targeting. BMC Cancer 2009 0.92
34 Characterization and tissue-specific expression of human GSK-3-binding proteins FRAT1 and FRAT2. Gene 2002 0.92
35 Lung cancer prevention: the guidelines. Chest 2003 0.91
36 Retinoic acid represses a cassette of candidate pluripotency chromosome 12p genes during induced loss of human embryonal carcinoma tumorigenicity. Biochim Biophys Acta 2005 0.91
37 Evidence for the ubiquitin protease UBP43 as an antineoplastic target. Mol Cancer Ther 2012 0.91
38 Evidence for tankyrases as antineoplastic targets in lung cancer. BMC Cancer 2013 0.90
39 Lysosomes and trivalent arsenic treatment in acute promyelocytic leukemia. J Natl Cancer Inst 2007 0.89
40 Retinoid targeting of different D-type cyclins through distinct chemopreventive mechanisms. Cancer Res 2005 0.89
41 Tumor-suppressive microRNAs in Lung cancer: diagnostic and therapeutic opportunities. ScientificWorldJournal 2009 0.87
42 Retinoid targets in cancer therapy and chemoprevention. Cancer Biol Ther 2003 0.86
43 Inhibiting retinoic acid signaling ameliorates graft-versus-host disease by modifying T-cell differentiation and intestinal migration. Blood 2013 0.85
44 The retinoic acid paradox in cancer chemoprevention. J Natl Cancer Inst 2006 0.83
45 Uncovering novel targets for cancer chemoprevention. Recent Results Cancer Res 2007 0.82
46 Repression of cyclin D1 as a target for germ cell tumors. Int J Oncol 2007 0.82
47 Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancer. Mol Cancer Ther 2013 0.80
48 Response to inhibition of smoothened in diverse epithelial cancer cells that lack smoothened or patched 1 mutations. Int J Oncol 2012 0.80
49 Retinoid chemoprevention trials: cyclin D1 in the crosshairs. Cancer Prev Res (Phila) 2009 0.79
50 Nonclassical retinoids and lung carcinogenesis. Clin Lung Cancer 2005 0.78
51 Gene profiling uncovers retinoid target genes. Methods Mol Biol 2007 0.78
52 Fenretinide activates a distinct apoptotic pathway. J Natl Cancer Inst 2004 0.78
53 A phase I trial and in vitro studies combining ABT-751 with carboplatin in previously treated non-small cell lung cancer patients. Chemotherapy 2012 0.78
54 Repression of exogenous gene expression by the retinoic acid target gene G0S2. Int J Oncol 2013 0.77
55 Clinical link between p53 and angiogenesis in lung cancer. J Clin Oncol 2002 0.77
56 Combining cytotoxic chemotherapy with cyclooxygenase-2 inhibition. J Clin Oncol 2003 0.75
57 Tissue microarrays for hypothesis generation. J Natl Cancer Inst 2004 0.75